VABIOTECH

VABIOTECH has a strong focus on research and develop- ment of new products. The initial R&D activities that lead to the successful development of all the VABIOTECH’s commercialized human use vaccines including inactivated hepatitis A vaccine, plasma derived and recombinant hepa- titis B vaccine, inactivated Japanese encephalitis vaccine and oral cholera vaccine. The Company has achieved many significant development milestones that exemplify its core R&D competencies, inclusive of developing the first cell based, adjuvant A/H5N1 vaccine in Viet Nam in 2007.

Timeline of achieved R&D products:

1993: Inactivated Japanese encephalitis vaccine 1993: Plasma derived hepatitis B vaccine

1993: Oral cholera vaccine

2001: Inactivated hepatitis A vaccine

2001: Recombinant hepatitis B vaccine

2005: A/H5N1 Influenza vaccine

2009: Haemophilus infuenzae type b (Hib) conjugates vaccine 2010: Vero cell derived rabies vaccine

2011: A/H1N1 Influenza vaccine

Leave a Reply

Your email address will not be published. Required fields are marked *